# GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma

> **NCT00293423** · PHASE1,PHASE2 · COMPLETED · sponsor: **University of California, San Francisco** · enrollment: 96 (actual)

## Conditions studied

- Brain and Central Nervous System Tumors

## Interventions

- **BIOLOGICAL:** HSPPC-96
- **PROCEDURE:** Standard Surgical Resection

## Key facts

- **NCT ID:** NCT00293423
- **Lead sponsor:** University of California, San Francisco
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-11-18
- **Primary completion:** 2013-01-12
- **Final completion:** 2013-01-12
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2021-05-13

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00293423

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00293423, "GP96 Heat Shock Protein-Peptide Complex Vaccine in Treating Patients With Recurrent or Progressive Glioma". Retrieved via AI Analytics 2026-08-13 from https://api.ai-analytics.org/clinical/NCT00293423. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*